Clinical Trials Logo

Refractory Visual Pathway Glioma clinical trials

View clinical trials related to Refractory Visual Pathway Glioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02780804 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT01089101 Active, not recruiting - Low Grade Glioma Clinical Trials

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Start date: April 19, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.